# Siponimod (Mayzent)

Source: https://ourhealthnetwork.com/drugs/siponimod
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Siponimod?

Siponimod (brand name: Mayzent) is a sphingosine 1-phosphate receptor modulator. It is prescribed to treat multiple sclerosis, chronic progressive, multiple sclerosis. Across the United States, 251 doctors prescribe Siponimod to approximately 62 Medicare patients.

## Brand names

Mayzent

## Indications

Siponimod is prescribed for several conditions including multiple sclerosis, chronic progressive, multiple sclerosis, among others.

## Conditions treated

- [Multiple Sclerosis](https://ourhealthnetwork.com/conditions/multiple-sclerosis)
- [Chronic Progressive](https://ourhealthnetwork.com/conditions/chronic-progressive)
- [Multiple Sclerosis](https://ourhealthnetwork.com/conditions/multiple-sclerosis)
- [Relapsing-Remitting](https://ourhealthnetwork.com/conditions/relapsing-remitting)

## Mechanism of action

Siponimod is an S1P receptor modulator. Siponimod binds with high affinity to S1P receptors 1 and 5.

## Drug classification

- Established Pharmacologic Class: Sphingosine 1-phosphate Receptor Modulator [EPC]
- Mechanism of Action class: Sphingosine 1-Phosphate Receptor Modulators [MoA]
- Route of administration: ORAL

## Common side effects

headache, hypertension, transaminase increases

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)